Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 16/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 14/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 13/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13614427 | 1.00 | P2RY2 (0.57) | P2RY2P2RY6P2RY4NT5EP2RY14 | |
| SCHEMBL14017252 | 0.86 | P2RY6 (0.58) | P2RY2P2RY6P2RY4NT5EP2RY14 | |
| SCHEMBL13614469 | 0.86 | P2RY6 (0.58) | P2RY2P2RY6P2RY4NT5EP2RY14 | |
| SCHEMBL13614844 | 0.85 | P2RY4 (0.52) | P2RY2P2RY6P2RY4NT5EP2RY14 | |
| SCHEMBL13614467 | 0.84 | P2RY6 (0.57) | P2RY2P2RY6P2RY4NT5EP2RY14 | |
| SCHEMBL13614843 | 0.84 | P2RY6 (0.57) | P2RY2P2RY6P2RY4NT5EP2RY14 | |
| SCHEMBL31260669 | 0.78 | P2RY2 (0.74) | P2RY2P2RY6P2RY4 | |
| SCHEMBL31260660 | 0.78 | P2RY2 (0.77) | P2RY2P2RY6P2RY4 | |
| SCHEMBL16809025 | 0.78 | P2RY2 (0.77) | P2RY2P2RY6P2RY4 | |
| SCHEMBL13614425 | 0.76 | P2RY6 (0.64) | P2RY2P2RY6P2RY4NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2647382-A1 | Compositions and methods for treating epithelial and retinal tissue diseases | Inspire Pharmaceuticals, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| US-7612047-B2 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | DOUGLASS III JAMES G | 2009-03-19 | — | — | US | disclosed |
| US-7435724-B2 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICAL, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435724-B2 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICAL, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20070244068-A1 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244068-A1 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244068-A1 | Degradation-resistant mononucleoside phosphate compounds | PNKP, ENTPD5, ENPP1 | P2RY2 75/4885P2RY6 39/4885P2RY4 74/4885 |
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | PNKP, ENTPD5, ENPP1 | P2RY2 75/4885P2RY6 39/4885P2RY4 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.